Claims
- 1. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically pure ester (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium with enantiomeric purity of 90% minimum enantiometric excess (ee), in an effective amount to a patient in need thereof.
- 2. The method according to claim 1, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 3. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 4. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 5. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.
- 6. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 7. The method according to claim 1, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 8. The method according to claim 1, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 9. The method according to claim 2, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the fort of an aerosol formulation.
- 10. The method according to claim 2, wherein the (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 11. The method according to claim 2, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 12. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically pure ester (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium with enantiomeric purity of 90% minimum enantiomeric excess (ee), in an effective amount to a patient in need thereof.
- 13. The method according to claim 12, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 14. The method according to claim 12, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 15. The method according to claim 12, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 16. The method according to claim 12, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.
- 17. The method according to claim 12, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 18. The method according to claim 12, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 19. The method according to claim 12, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 20. The method according to claim 13, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 21. The method according to claim 13, wherein the (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 22. The method according to claim 13, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
Priority Claims (1)
Number |
Date |
Country |
Kind |
1973/96 |
Nov 1996 |
AT |
|
CROSS REFERENCE TO RELATED APPLICATION
This is a continuation-in-part of application Ser. No. 09/309,960, filed on May 11, 1999, now U.S. Pat. No. 6,307,060 which is a continuation of PCT/AT97/00245 filed Nov. 11, 1997.
Non-Patent Literature Citations (1)
Entry |
Haddad et al., Pharmacological characteristics of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea pig airways, British Journal of Pharmacology 127 (2): 413-420, 1999. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/AT97/00245 |
Nov 1997 |
US |
Child |
09/309960 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/309960 |
May 1999 |
US |
Child |
09/901217 |
|
US |